© Copyright 2009 by the Society for Neuro-Oncology
Received July 17, 2008
Accepted February 25, 2009
Imaging of integrin 
v
3 expression in patients with malignant glioma by [18F]galacto-RGD positron emission tomography
Oliver Schnell 1,
Bjarne Krebs 2,
Janette Carlsen 3,
Isabelle Miederer 3,
Claudia Goetz 1,
Roland H. Goldbrunner 1,
Hans-Jürgen Wester 3,
Roland Haubner 4,
Gabriele Pöpperl 5,
Markus Holtmannspötter 6,
Hans A. Kretzschmar 7,
Horst Kessler 8,
Jörg-Christian Tonn 9,
Markus Schwaiger 10,
Ambros J. Beer 3*
1 Department of Neurosurgery, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
2 Center for Neuropathology and Prion Research, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
3 Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
4 Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Austria
5 Department of Nuclear Medicine, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
6 Department of Neuroradiology, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
7 Center for Neuropathology and Prion Research, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
8 Center of Integrated Protein Science, Department of Chemistry, Technische Universität München, Garching, Germany
9 Department of Neurosurgery, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany
10 Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
* To whom correspondence should be addressed. E-mail: beer{at}roe.med.tum.de.
 |
Abstract |
|---|
Inhibitors targeting the integrin 
v
3 are promising new agents currently tested in clinical trials for supplemental therapy of glioblastoma multiforme (GBM). The aim of our study was to evaluate [18F]Galacto-RGD positron emission tomography (PET) for non-invasive imaging of v3 expression in patients with GBM suggesting eligibility for this kind of additional treatment. Patients with suspected or recurrent GBM were examined with [18F]Galacto-RGD PET. Standardized uptake values (SUVs) of tumor hotspots, galea and blood pool were derived by region-of-interest analysis. [18F]Galacto-RGD PET images were fused with cranial MRI scans for image guided surgery. Tumor samples taken from areas with intense tracer accumulation in the [18F]Galacto-RGD PET were analyzed histologically and immunhistochemically for v3 integrin expression. While normal brain tissue did not show significant tracer accumulation (mean SUV 0.09 ± 0.04), GBMs demonstrated significant but heterogeneous tracer uptake with a maximum in the highly proliferating and infiltrating areas of tumors (mean SUV 1.6 ± 0.5). Immunohistochemical staining was prominent in tumor microvessels as well as glial tumor cells. In areas of highly proliferating glial tumor cells, tracer uptake (SUVs) in the [18F]Galacto-RGD PET correlated to the immunohistochemical v3 integrin expression of corresponding tumor samples. These data suggest that [18F]Galacto-RGD PET successfully identifies v3 expression in patients with GBM and might be a promising tool for planning and monitoring individualized cancer therapies targeting this integrin.
Key Words:
malignant glioma, v3, integrins, intellectual impairment, [18F]Galacto-RGD, PET, angiogenesis
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
